How can we manage progressive supranuclear palsy syndrome with pharmacotherapy?

References

• Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol. 2013;12(6):609–622.
   PubMed Web of Science ®Google Scholar
• Josephs KA. Current understanding of neurodegenerative diseases associated with the protein tau. Mayo Clin Proc. 2017;92(8):1291–1303. doi: 10.1016/j.mayocp.2017.04.016
   PubMed Web of Science ®Google Scholar
• Panza F, Lozupone M, Seripa D, et al. Development of disease-modifying drugs for frontotemporal dementia spectrum disorders. Nat Rev Neurol. 2020;16(4):213–228. doi: 10.1038/s41582-020-0330-x
   PubMed Web of Science ®Google Scholar
• Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (steele-richardson-olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology. 1996;47(1):1–9. doi: 10.1212/wnl.47.1.1
   PubMed Web of Science ®Google Scholar
• Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol. 1964;10(4):333–359. doi: 10.1001/archneur.1964.00460160003001
   PubMedGoogle Scholar
• Boxer AL, Yu JT, Golbe LI, et al. Advances in progressive supranuclear palsy: new diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017;6(7):552–563. doi: 10.1016/S1474-4422(17)30157-6
   Google Scholar
• Respondek G, Stamelou M, Kurz C, et al. The phenotypic spectrum of progressive supranuclear palsy: a retrospective multicenter study of 100 definite cases. Mov Disord. 2014;29(14):1758–1766. doi: 10.1002/mds.26054
   PubMed Web of Science ®Google Scholar
• Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive supranuclear palsy. Acta Neuropathol. 2020;140(2):99–119. doi: 10.1007/s00401-020-02158-2
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Respondek G, Stamelou M, et al. Movement disorder society-endorsed PSP study group. Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria. Mov Disord. 2017;32(6):853–864. doi: 10.1002/mds.26987
   PubMed Web of Science ®Google Scholar
• van Eimeren T, Antonini A, Berg D, et al. Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a neuroimaging biomarker utility system. Alz & Dem Diag Ass & Dis Mo. 2019;11(1):301–309. doi: 10.1016/j.dadm.2019.01.011
   PubMedGoogle Scholar
• McFarland NR. Diagnostic approach to atypical parkinsonian syndromes. Continuum (Minneap Minn). 2016;22(4 Movement Disorders):1117–1142. doi: 10.1212/CON.0000000000000348
   PubMedGoogle Scholar
• Bluett B, Litvan I. Pathophysiology, genetics, clinical features, diagnosis and therapeutic trials in progressive supranuclear palsy. Expert Opin Orphan Drugs. 2015;3(3):253–265. doi: 10.1517/21678707.2015.1018180
   Web of Science ®Google Scholar
• Coyle-Gilchrist IT, Dick KM, Patterson K, et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology. 2016;86(18):1736–1743. doi: 10.1212/WNL.0000000000002638
   PubMed Web of Science ®Google Scholar
• Franzmeier N, Brendel M, Beyer L, et al. Tau deposition patterns are associated with functional connectivity in primary tauopathies. Nat Commun. 2022;13(1):1362. doi: 10.1038/s41467-022-28896-3
   PubMed Web of Science ®Google Scholar
• Darricau M, Katsinelos T, Raschella F, et al. Tau seeds from patients induce progressive supranuclear palsy pathology and symptoms in primates. Brain. 2023;146(6):2524–2534. doi: 10.1093/brain/awac428
   PubMed Web of Science ®Google Scholar
• Veilleux Carpentier A, McFarland NR. Progressive supranuclear palsy: current approach and challenges to diagnosis and treatment. Curr Opin Neurol. 2023;36(4):309–316. doi: 10.1097/WCO.0000000000001163
   PubMed Web of Science ®Google Scholar
• Holmes BB, Diamond MI. Prion-like properties of tau protein: the importance of extracellular tau as a therapeutic target. J Biol Chem. 2014;289(29):19855–19861. doi: 10.1074/jbc.R114.549295
   PubMed Web of Science ®Google Scholar
• Horie K, Barthélemy NR, Sato C, et al. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer’s disease. Brain. 2021;144(2):515–527. doi: 10.1093/brain/awaa373
   PubMed Web of Science ®Google Scholar
• Boxer AL, Qureshi I, Ahlijanian M, et al. Safety of the tau- directed monoclonal antibody BIIB092 in progressive supranuclear palsy: a randomised, placebo- controlled, multiple ascending dose phase 1b trial. Lancet Neurol. 2019;18(6):549–558. doi: 10.1016/S1474-4422(19)30139-5
   PubMed Web of Science ®Google Scholar
• Dam T, Boxer AL, Golbe LI, et al. Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial. Nat Med. 2021;27(8):1451–1457. doi: 10.1038/s41591-021-01455-x
   PubMed Web of Science ®Google Scholar
• Höglinger GU, Litvan I, Mendonca N, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial. Lancet Neurol. 2021;20(3):182–192. doi: 10.1016/S1474-4422(20)30489-0
   PubMed Web of Science ®Google Scholar
• Koga S, Dickson DW, Wszolek ZK. Neuropathology of progressive supranuclear palsy after treatment with tilavonemab. Lancet Neurol. 2021;20(10):786–787. doi: 10.1016/S1474-4422(21)00283-0
   PubMed Web of Science ®Google Scholar
• Beck G, Yamashita R, Kido K, et al. An autopsy case of progressive supranuclear palsy treated with monoclonal antibody against tau. Neuropathology. 2023;43(4):326–332. doi: 10.1111/neup.12890
   PubMed Web of Science ®Google Scholar
• Kim B, Mikytuck B, Suh E, et al. Tau immunotherapy is associated with glial responses in FTLD-tau. Acta Neuropathol. 2021;142(2):243–257. doi: 10.1007/s00401-021-02318-y
   PubMed Web of Science ®Google Scholar
• Courade JP, Angers R, Mairet-Coello G, et al. Epitope determines efficacy of therapeutic anti-tau antibodies in a functional assay with human alzheimer tau. Acta Neuropathol. 2018;136(5):729–745. doi: 10.1007/s00401-018-1911-2
   PubMed Web of Science ®Google Scholar
• Panza F, Imbimbo BP, Lozupone M, et al. Disease-modifying therapies for tauopathies: agents in the pipeline. Expert Rev Neurother. 2019;19(5):397–408. doi: 10.1080/14737175.2019.1606715
   PubMed Web of Science ®Google Scholar
• Cullen NC, Novak P, Tosun D, et al. Efficacy assessment of an active tau immunotherapy in Alzheimer’s disease patients with amyloid and tau pathology: a post hoc analysis of the “ADAMANT” randomised, placebo-controlled, double-blind, multi-centre, phase 2 clinical trial. EBioMedicine. 2023;99:104923. doi: 10.1016/j.ebiom.2023.104923
   PubMed Web of Science ®Google Scholar
• Vulih-Shultzman I, Pinhasov A, Mandel S, et al. Activity- dependent neuroprotective protein snippet NAP reduces tau hyperphosphorylation and enhances learning in a novel transgenic mouse model. J Pharmacol Exp Ther. 2007;323(2):438–449. doi: 10.1124/jpet.107.129551
   PubMed Web of Science ®Google Scholar
• Tsai RM, Miller Z, Koestler M, et al. Reactions to multiple ascending doses of the microtubule stabilizer TPI-287 in patients with alzheimer disease, progressive supranuclear palsy, and corticobasal syndrome: a randomized clinical trial. JAMA Neurol. 2020;77(2):215–224. doi: 10.1001/jamaneurol.2019.3812
   PubMed Web of Science ®Google Scholar
• Leclair-Visonneau L, Rouaud T, Debilly B, et al. Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy. Clin Neurol Neurosur. 2016;146:35–39. doi: 10.1016/j.clineuro.2016.04.021
   PubMed Web of Science ®Google Scholar
• Tolosa E, Litvan I, Höglinger GU, et al. A phase 2 trial of the GSK-3 inhibitor tideglusib in progressive supranuclear palsy. Mov Disord. 2014;29(4):470–478. doi: 10.1002/mds.25824
   PubMed Web of Science ®Google Scholar
• Borghgraef P, Menuet C, Theunis C, et al. Increasing brain protein O-GlcNAcylation mitigates breathing defects and mortality of Tau.P301L mice. PLOS ONE. 2013;8(12):e84442. doi: 10.1371/journal.pone.0084442
   PubMed Web of Science ®Google Scholar
• Hastings NB, Wang X, Song L, et al. Inhibition of O-GlcNAcase leads to elevation of OGlcNAc tau and reduction of tauopathy and cerebrospinal fluid tau in rTg4510 mice. Mol Neurodegener. 2017;12(1):39. doi: 10.1186/s13024-017-0181-0
   PubMedGoogle Scholar
• [cited 2014 Mar 30]. Avaliable from: https://www.alzforum.org/therapeutics/asn90
   Google Scholar
• Albers DS, Swerdlow RH, Manfredi G, et al. Further evidence for mitochondrial dysfunction in progressive supranuclear palsy. Exp Neurol. 2001;168(1):196–198. doi: 10.1006/exnr.2000.7607
   PubMed Web of Science ®Google Scholar
• Park LC, Albers DS, Xu H, et al. Mitochondrial impairment in the cerebellum of the patients with progressive supranuclear palsy. J Neurosci Res. 2001;66(5):1028–1034. doi: 10.1002/jnr.10062
   PubMed Web of Science ®Google Scholar
• Di Monte DA, Harati Y, Jankovic J, et al. Muscle mitochondrial ATP production in progressive supranuclear palsy. J Neurochem. 1994;62(4):1631–1634. doi: 10.1046/j.1471-4159.1994.62041631.x
   PubMed Web of Science ®Google Scholar
• Martinelli P, Scaglione C, Lodi R, et al. Deficit of brain and skeletal muscle bioenergetics in progressive supranuclear palsy shown in vivo by phosphorus magnetic resonance spectroscopy. Mov Disorder. 2000;15:889–893. doi: 10.1002/1531-8257(200009)15:5<889:aid-mds1020>3.0.co;2-t
   PubMed Web of Science ®Google Scholar
• Stamelou M, Reuss A, Pilatus U, et al. Short-term effects of coenzyme Q10 in progressive supranuclear palsy: a randomized, placebo-controlled trial. Mov Disord. 2008;23(7):942–949. doi: 10.1002/mds.22023
   PubMed Web of Science ®Google Scholar
• Apetauerova D, Scala SA, Hamill RW, et al. CoQ10 in progressive supranuclear palsy: a randomized, placebo-controlled, double-blind trial. Neurol(r) Neuroimmunol Neuroinflammation. 2016;3(5):e266. doi: 10.1212/NXI.0000000000000266
   PubMed Web of Science ®Google Scholar
• [cited 2024 Mar 30]. Available from: https://www.retrotope.com/press-release/retrotope-announces-completion-of-enrollment-in-phase-2-study-of-rt001-in-patients-with-progressive-supranuclear-palsy-psp/
   Google Scholar
• Hubsch C, Ivan Mari MZ, Léguillier T, et al. Subcutaneous apomorphine in the treatment of progressive supranuclear palsy and corticobasal syndrome: a preliminary study of 7 cases. Parkinsonism Relat Disord. 2022;95:98–99. doi: 10.1016/j.parkreldis.2021.11.026
   PubMed Web of Science ®Google Scholar
• [cited 2024 Mar 30]. Available from: https://ccpp.cam.ac.uk/ClinicalTrials/clinical-trial-a-noradrenergic-therapy
   Google Scholar
• Lozupone M, Dibello V, Sardone R, et al. The development of peptide- and oligonucleotide-based drugs to prevent the formation of abnormal tau in tauopathies. Expert Opin Drug Discov. 2023;18(5):515–526. doi: 10.1080/17460441.2023.2200245
   PubMed Web of Science ®Google Scholar
• DeVos SL, Miller RL, Schoch KM, et al. Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy. Sci Transl Med. 2017;9(374):eaag0481. doi: 10.1126/scitranslmed.aag0481
   PubMed Web of Science ®Google Scholar
• Vacchi E, Lazzarini E, Pinton S, et al. Tau protein quantification in skin biopsies differentiates tauopathies from alpha-synucleinopathies. Brain. 2022;145(8):2755–2768. doi: 10.1093/brain/awac161
   PubMed Web of Science ®Google Scholar
• Shi Y, Zhang W, Yang Y, et al. Structure-based classification of tauopathies. Nature. 2021;598:359–363. doi: 10.1038/s41586-021-03911-7
   PubMed Web of Science ®Google Scholar
• Jabbari E, Duff KE. Tau-targeting antibody therapies: too late, wrong epitope or wrong target? Nat Med. 2021;27(8):1341–1342. doi: 10.1038/s41591-021-01465-9
   PubMed Web of Science ®Google Scholar
• [cited 2024 Mar 30]. Available from: https://www.alzforum.org/news/conference-coverage/block-taus-proteopathic-spread-antibody-must-attack-its-mid-region
   Google Scholar
• Tawana K, Ramsden DB. Progressive supranuclear palsy. Mol Pathol. 2001;54(6):427–434.
   PubMedGoogle Scholar
• Alavi Naini SM, Soussi-Yanicostas N. Tau hyperphosphorylation and oxidative stress, a critical vicious circle in neurodegenerative tauopathies? OxidMed Cell Longevity. 2015;2015:151979. doi: 10.1155/2015/151979
   PubMed Web of Science ®Google Scholar
• Matsuoka K, Takado Y, Tagai K, et al. Two pathways differentially linking tau depositions, oxidative stress, and neuronal loss to apathetic phenotypes in progressive supranuclear palsy. J Neurol Sci. 2023;444:120514. doi: 10.1016/j.jns.2022.120514
   PubMed Web of Science ®Google Scholar
• Evans LD, Strano A, Campbell A, et al. Whole genome CRISPR screens identify LRRK2-regulated endocytosis as a major mechanism for extracellular tau uptake by human neurons. bioRxiv. 2020 Aug 11;246363. doi: 10.1101/2020.08.11.246363
   Google Scholar
• Myeku N, Clelland CL, Emrani S, et al. Tau-driven 26S proteasome impairment and cognitive dysfunction can be prevented early in disease by activating cAMP-PKA signaling. Nat Med. 2016;22(1):46–53. doi: 10.1038/nm.4011
   PubMed Web of Science ®Google Scholar